Predicting Oral Drug Absorption: Mini Review on Physiologically-Based Pharmacokinetic Models

Most marketed drugs are administered orally, despite the complex process of oral absorption that is difficult to predict. Oral bioavailability is dependent on the interplay between many processes that are dependent on both compound and physiological properties. Because of this complexity, computational oral physiologically-based pharmacokinetic (PBPK) models have emerged as a tool to integrate these factors in an attempt to mechanistically capture the process of oral absorption. These models use inputs from in vitro assays to predict the pharmacokinetic behavior of drugs in the human body. The most common oral PBPK models are compartmental approaches, in which the gastrointestinal tract is characterized as a series of compartments through which the drug transits. The focus of this review is on the development of oral absorption PBPK models, followed by a brief discussion of the major applications of oral PBPK models in the pharmaceutical industry.

[1]  Utilizing physiologically based pharmacokinetic modeling to inform formulation and clinical development for a compound with pH-dependent solubility. , 2015, Journal of pharmaceutical sciences.

[2]  K. Higaki,et al.  Prediction of the Plasma Concentration Profiles of Orally Administered Drugs in Rats on the Basis of Gastrointestinal Transit Kinetics and Absorbability , 1997, The Journal of pharmacy and pharmacology.

[3]  Ayman El-Kattan,et al.  Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. , 2007, Expert opinion on drug metabolism & toxicology.

[4]  M. Kataoka,et al.  Analysis of Intra- and Intersubject Variability in Oral Drug Absorption in Human Bioequivalence Studies of 113 Generic Products. , 2015, Molecular pharmaceutics.

[5]  Malcolm Rowland,et al.  PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. , 2011, Journal of pharmaceutical sciences.

[6]  T. Baillie,et al.  Extrapolation of Diclofenac Clearance from in Vitro Microsomal Metabolism Data: Role of Acyl Glucuronidation and Sequential Oxidative Metabolism of the Acyl Glucuronide , 2002, Journal of Pharmacology and Experimental Therapeutics.

[7]  R. M. Owen,et al.  An analysis of the attrition of drug candidates from four major pharmaceutical companies , 2015, Nature Reviews Drug Discovery.

[8]  X. Chu,et al.  Species differences in drug transporters and implications for translating preclinical findings to humans , 2013, Expert opinion on drug metabolism & toxicology.

[9]  D. Flanagan,et al.  General solution for diffusion-controlled dissolution of spherical particles. 1. Theory. , 1999, Journal of pharmaceutical sciences.

[10]  Hywel D Williams,et al.  Strategies to Address Low Drug Solubility in Discovery and Development , 2013, Pharmacological Reviews.

[11]  J. Dressman,et al.  Mixing-tank model for predicting dissolution rate control or oral absorption. , 1986, Journal of pharmaceutical sciences.

[12]  Gordon L Amidon,et al.  A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals , 2002, Journal of clinical pharmacology.

[13]  Yuichi Sugiyama,et al.  In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. , 2009, Drug metabolism and pharmacokinetics.

[14]  Lawrence X. Yu,et al.  Compartmental transit and dispersion model analysis of small intestinal transit flow in humans , 1996 .

[15]  Gordon L. Amidon,et al.  The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon , 1987, Journal of Pharmacokinetics and Biopharmaceutics.

[16]  J. Dressman,et al.  Estimating drug solubility in the gastrointestinal tract. , 2007, Advanced drug delivery reviews.

[17]  Michael Gertz,et al.  Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction , 2011, Drug Metabolism and Disposition.

[18]  Torsten Teorell,et al.  Kinetics of distribution of substances administered to the body, II : The intravascular modes of administration , 1937 .

[19]  C. Prakash,et al.  Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist , 2015, Drug Metabolism and Disposition.

[20]  Xiaomei Zhuang,et al.  Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA‐14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction , 2014, Biopharmaceutics & drug disposition.

[21]  Keith W. Ward,et al.  Optimizing Pharmacokinetic Properties and Attaining Candidate Selection , 2012 .

[22]  J.M. Bailey,et al.  A simple analytical solution to the three-compartment pharmacokinetic model suitable for computer-controlled infusion pumps , 1991, IEEE Transactions on Biomedical Engineering.

[23]  T. Mano,et al.  Solubility and dissolution profile assessment in drug discovery. , 2007, Drug metabolism and pharmacokinetics.

[24]  G. Amidon,et al.  Physiological parameters for oral delivery and in vitro testing. , 2010, Molecular pharmaceutics.

[25]  Xavier Pepin,et al.  Mechanistic investigation of the negative food effect of modified release zolpidem , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[26]  L. Benet,et al.  Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy , 1995, Molecular carcinogenesis.

[27]  G. Amidon,et al.  Physicochemical model for dose-dependent drug absorption. , 1984, Journal of pharmaceutical sciences.

[28]  P. Welling,et al.  Effects of food on drug absorption. , 1989, Pharmacology & therapeutics.

[29]  Po-Chang Chiang,et al.  Incorporation of Physiologically Based Pharmacokinetic Modeling in the Evaluation of Solubility Requirements for the Salt Selection Process: A Case Study Using Phenytoin , 2013, The AAPS Journal.

[30]  K. Maeda,et al.  Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.

[31]  M. Jamei,et al.  A Novel Physiologically-Based Mechanistic ModelPredicting Oral Drug Absorption: The Advanced Dissolution, Absorption, and Metabolism (ADAM) Model , 2007 .

[32]  Lin Yang,et al.  Mechanistic prediction of food effects for Compound A tablet using PBPK model , 2017, Saudi journal of biological sciences.

[33]  A. Glomme,et al.  Predicting the Intestinal Solubility of Poorly Soluble Drugs , 2007 .

[34]  Y Zhang,et al.  Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. , 1998, Journal of pharmaceutical sciences.

[35]  T. Murakami,et al.  Intestinal efflux transporters and drug absorption. , 2008, Expert opinion on drug metabolism & toxicology.

[36]  Morton B. Brown,et al.  Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine , 1997, Clinical pharmacology and therapeutics.

[37]  G. Amidon,et al.  Description and simulation of a multiple mixing tank model to predict the effect of bile sequestrants on bile salt excretion. , 1993, Journal of pharmaceutical sciences.

[38]  D. Shen,et al.  Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.

[39]  B Agoram,et al.  Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.

[40]  Kevin C. Johnson,et al.  Guidance in the Setting of Drug Particle Size Specifications to Minimize Variability in Absorption , 1996, Pharmaceutical Research.

[41]  Lawrence X. Yu An Integrated Model for Determining Causes of Poor Oral Drug Absorption , 1999, Pharmaceutical Research.

[42]  Neil Parrott,et al.  Applications of physiologically based absorption models in drug discovery and development. , 2008, Molecular pharmaceutics.

[43]  John P. Rose,et al.  Developability assessment of clinical drug products with maximum absorbable doses. , 2012, International journal of pharmaceutics.

[44]  B. Hirst,et al.  P-glycoprotein Potentiates CYP3A4-mediated Drug Disappearance during Caco-2 Intestinal Secretory Detoxification , 2004, Journal of drug targeting.

[45]  R. Upton,et al.  Food, gastrointestinal pH, and models of oral drug absorption , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[46]  G. Amidon,et al.  Absorption potential: estimating the fraction absorbed for orally administered compounds. , 1985, Journal of pharmaceutical sciences.

[47]  A. Noyes,et al.  The rate of solution of solid substances in their own solutions , 1897 .

[48]  H Lennernäs,et al.  Membrane transport of drugs in different regions of the intestinal tract of the rat. , 1998, Journal of pharmaceutical sciences.

[49]  M. Paine,et al.  P-Glycoprotein Increases from Proximal to Distal Regions of Human Small Intestine , 2003, Pharmaceutical Research.

[50]  Lawrence X. Yu,et al.  In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome. , 2004, Current opinion in drug discovery & development.

[51]  P. Breen,et al.  Drug dissolution: significance of physicochemical properties and physiological conditions. , 2013, Drug discovery today.

[52]  Hefei Zhang,et al.  Application of Physiologically Based Absorption Modeling to Formulation Development of a Low Solubility, Low Permeability Weak Base: Mechanistic Investigation of Food Effect , 2014, AAPS PharmSciTech.